羟氯喹用于COVID-19暴露前预防:一项双盲、安慰剂对照随机临床试验
在西班牙巴塞罗那三家医院开展的双盲安慰剂对照随机临床试验,纳入269名无SARS-CoV-2感染证据的成人医护人员,比较羟氯喹暴露前预防与安慰剂的疗效与安全性。因全国流行发病率下降,每组仅1例诊断为COVID-19,试验因无效而停止,设计被认为把握度不足无法评估预防疗效;两组不良事件比例相似(p=0.548),无严重不良事件,羟氯喹组轻度胃肠道症状显著高于安慰剂组(27.4% vs 15.7%,p=0.041)。
要点
- 因全国流行发病率下降,每组仅1例诊断为COVID-19,试验因无效停止,设计把握度不足无法评估预防疗效。
- 两组经历至少一次不良事件的比例相似(p=0.548),无严重不良事件报告。
- 羟氯喹组轻度胃肠道症状显著高于安慰剂组(27.4% vs 15.7%,p=0.041)。
核心结论
- 尽管羟氯喹暴露前预防COVID-19的疗效无法评估,但研究表明低剂量羟氯喹暴露前预防是安全的。
研究设计与样本
- 在西班牙巴塞罗那三家医院开展的双盲、安慰剂对照随机临床试验,筛查350名成人医护人员,纳入269名无活动性或既往SARS-CoV-2感染的参与者(鼻咽SARS-CoV-2 PCR阴性且SARS-CoV-2血清学阴性)。
- 干预组(暴露前预防)前连续4天每日接受400 mg羟氯喹,随后在研究期间每周400 mg;对照组按相同方案服用安慰剂片。
- 52.8%(142/269)的参与者分配至羟氯喹组,47.2%(127/269)分配至安慰剂组。
主要发现
- 因全国流行发病率下降,每组仅1例参与者诊断为COVID-19。
- 试验因无效而停止,研究设计被认为把握度不足,无法评估暴露前预防疗效方面的任何获益。
- 两组经历至少一次不良事件的参与者比例相似(p=0.548),未报告严重不良事件。
- 几乎所有不良事件(96.4%,106/110)为轻度。
- 仅轻度胃肠道症状在羟氯喹组显著高于安慰剂组(27.4%(39/142)vs 15.7%(20/127),p=0.041)。
关键数值与推荐
- 羟氯喹组轻度胃肠道症状27.4%(39/142)vs 安慰剂组15.7%(20/127),p=0.041。
- 两组至少一次不良事件比例相似,p=0.548。
- 不良事件中轻度占96.4%(106/110)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因全国流行发病率下降,每组仅1例诊断为COVID-19。
- 试验因无效而停止,研究设计被认为把握度不足,无法评估暴露前预防疗效方面的任何获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-exposure prophylaxis (PrEP) is a promising strategy to break COVID-19 transmission. Although hydroxychloroquine was evaluated for treatment and post-exposure prophylaxis, it is not evaluated for COVID-19 PrEP yet. The aim of this study was to evaluate the efficacy and safety of PrEP with hydroxychloroquine against placebo in healthcare workers at high risk of SARS-CoV-2 infection during an epidemic period. METHODS: We conducted a double-blind placebo-controlled randomized clinical trial in three hospitals in Barcelona, Spain. From 350 adult healthcare workers screened, we included 269 participants with no active or past SARS-CoV-2 infection (determined by a negative nasopharyngeal SARS-CoV-2 PCR and a negative serology against SARS-CoV-2). Participants allocated in the intervention arm (PrEP) received 400 mg of hydroxychloroquine daily for the first four consecutive days and subsequently, 400 mg weekly during the study period. Participants in the control group followed the same treatment schedule with placebo tablets. RESULTS: 52.8% (142/269) of participants were in the hydroxychloroquine arm and 47.2% (127/269) in the placebo arm. Given the national epidemic incidence decay, only one participant in each group was diagnosed with COVID-19. The trial was stopped due to futility and our study design was deemed underpowered to evaluate any benefit regarding PrEP efficacy. Both groups showed a similar proportion of participants experiencing at least one adverse event (AE) (p=0.548). No serious AEs were reported. Almost all AEs (96.4%, 106/110) were mild. Only mild gastrointestinal symptoms were significantly higher in the hydroxychloroquine arm compared to the placebo arm (27.4% (39/142) vs 15.7% (20/127), p=0.041). CONCLUSIONS: Although the efficacy of PrEP with hydroxychloroquine for preventing COVID-19 could not be evaluated, our study showed that PrEP with hydroxychloroquine at low doses is safe. TRIAL REGISTRATION: ClinicalTrials.gov NCT04331834 . Registered on April 2, 2020.
引用
- Grau-Pujol B, Camprubí-Ferrer D, Marti-Soler H, et al. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. Trials. 2021. PMID: 34781981. doi:10.1186/s13063-021-05758-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。